Pharmaceutical Strategy Consulting

Tailored solutions for successful pharmaceutical development and market access in China and across the Asia Pacific region.

China and the Asia Pacific region offer vast opportunities for pharmaceutical companies, but navigating these markets requires deep regulatory insight, clinical development expertise, and strategic foresight. Cisema supports international life sciences organizations with customized consulting services that span the full product lifecycle, from early-stage development to successful commercialization.

With over 20 years of regional expertise, we help ensure that your medical products meet evolving regulatory requirements, accelerate drug development timelines and achieve market access across diverse APAC jurisdictions. Our integrated approach combines regulatory strategy, clinical development support, and operational execution - tailored to the needs of start-ups, mid-size companies, and global pharmaceutical leaders.

Pharmaceutical Strategy Consulting
Cisema helping innovative products from research into commercialization
Life Sciences Consulting

We align regulatory compliance with business strategy, helping clients build capabilities and seize emerging growth opportunities. Whether you're preparing for clinical trials, navigating NMPA submissions, or expanding across ASEAN, South Korea, Japan, or Australia, our bilingual teams across Europe and Asia deliver accurate, timely, and compliant submissions.

Cisema’s consulting services are designed to support biotech innovators, life sciences companies, academia and clinical research organizations with strategic planning, data analytics, and regulatory intelligence. We work across the value chain - from clinical development to post-market lifecycle management - to define stakeholder value, optimize resource allocation, and improve patient outcomes.

Our China & APAC Pharmaceutical Consulting Services:

Whether you’re entering China or an APAC market for the first time, scaling operations, or seeking support during early-stage development, Cisema provides strategic guidance and regional regulatory expertise to help you navigate every phase of the pharmaceutical product lifecycle. With over 20 years of experience, we empower life sciences companies to make informed decisions and capture growth opportunities across Asia Pacific’s dynamic healthcare landscape.

Drug Development Strategy & Planning

We design development strategies that align clinical, regulatory, and commercial milestones with the diverse market conditions across Asia Pacific. Our roadmaps streamline submissions, eliminate barriers, and optimize resource allocation from concept to launch.

Regulatory & Clinical GAP Analysis

Our experts assess your documentation for alignment with local regulatory and clinical requirements. We identify gaps and provide actionable recommendations to support both innovative and generic drug submissions, reducing risk and improving approval efficiency.

Expedited Approval Pathways

We help you leverage fast-track designations, priority reviews, and conditional approvals available in China and other Asia Pacific markets. Our team guides you through eligibility assessments and application preparation to accelerate time to market.

Regulatory Authority Engagement & Submission Preparation

Acting as your liaison with national health authorities, we manage regulatory interactions, prepare submission-ready technical documentation, and ensure alignment with local standards for a smooth review process

Clinical Trial Strategy & Local Study Design

We evaluate the acceptability of foreign clinical data and determine the need for local trials. Our experts support protocol design, site selection, and operational management to ensure compliant and efficient clinical development.

Regulatory, Scientific & Medical Writing

We prepare high-quality documentation, including CTD modules, clinical summaries, and safety narratives, tailored to local regulatory expectations. Clear, well-structured submissions improve engagement with authorities and facilitate faster approvals.

Market Access & Commercial Strategy

Post-approval, we help position your product for commercial success through:

Pricing & Reimbursement: Including National Reimbursement Drug List pathway insights and health economics modeling.
Stakeholder Mapping: Engaging payers, Key Opinion Leaders, and hospital channels.
Competitor Benchmarking: Tailoring your value proposition to local market dynamics.

Why Work with Cisema?

Local expertise with global reach

Our bilingual teams bridge international quality standards with local regulations

Proven track record

Over 20 years supporting market approvals and compliance in China and Asia Pacific

End-to-end solutions

From system setup to post-market surveillance, we ensure quality management and regulatory compliance throughout the product lifecycle

Industry breadth

Cross-sector expertise in life sciences, food, veterinary, consumer and industrial goods

Role of a China Agent

Frequently Asked Questions

Common hurdles include data localization, fragmented and frequent regulatory updates, and strict post-market obligations. We help you address these early with clear strategies that reduce approval timelines and costs.

Early communication with national authorities clarifies requirements and minimizes risk. Our experts support pre-submission meetings, technical reviews, and strategic planning to set your submission up for success.

We assess eligibility and manage the entire process, from dossier preparation to interactions with regulators, to maximize your product’s chances of accelerated review.

Trials must meet local regulatory, ethical, and cultural expectations. We help design trials that comply with each country’s standards, leverage foreign data where applicable, and avoid delays.

We assist with pharmacovigilance, lifecycle management, and updates to maintain compliance with evolving regulations and market requirements.

Request a Proposal from Our Pharma Team

Let Cisema help turn your plans into reality.

Request Proposal

Explore Related Services

Pharmaceutical Regulatory Affairs

Navigate regulatory complexity across China and Asia Pacific with confidence. Our regulatory affairs consulting experts support life sciences companies with strategic planning, compliant submissions, and local representation to accelerate approvals and ensure market readiness.

Health Economics & Market Access

Accelerate access across China and Asia Pacific with confidence. Our market access consulting experts help life sciences companies optimize patient access, navigate pricing and reimbursement challenges, and enable commercial success through real world evidence, health economics, and tailored access strategies.

Pharmacovigilance

Ensure drug safety and regulatory compliance across China and Asia Pacific with confidence. Our pharmacovigilance consulting experts support life sciences companies in managing risks, meeting evolving safety requirements, and maintaining market authorization through end-to-end PV solutions tailored to local regulations.

Quality Management & Compliance

Ensure regulatory excellence across China and Asia Pacific with confidence. Our quality management and compliance experts help life sciences companies strengthen GxP systems, streamline audits, and maintain inspection readiness to safeguard market access and operational performance.

How We’ve Helped Clients with Our Expert Guidance

Read about how we work with clients to find solutions, bringing together deep industry knowledge with leading talent.

View More
April 18, 2026

China Manufacture License Renewal for Level A2 Pressure Vessels

How Cisema Supported Inox Torres Group, S.L. in Successfully Renewing its China Manufacture License (SELO) for Level A2 Pressure Vessels

The China Manufacture License (CML), also known as the SELO license, is a mandatory requirement for manufacturers of pressure equipment intended for the Chinese market. Inox Torres Group, S.L.’s manufacturing site produces high-pressure vessels falling under the Level A2 scope. This license ensures compliance with China’s stringent quality and safety regulations for special equipment.

The Challenge: Managing SELO Complexity for High-Risk Equipment

Renewing a SELO license for Level A2 pressure vessels required careful coordination across regulatory, technical, and cultural dimensions.

  • Navigating Regulatory Complexity
    Navigating the complex and evolving SELO regulatory framework, particularly for high-risk products under Level A2, required meticulous planning and real-time compliance updates.
  • Ensuring Audit Readiness
    Inox Torres Group, S.L. needed to ensure all documentation and procedures were fully up to date and to select an appropriate demo product that met inspection requirements.
  • Managing Inspector Expectations
    Success depended on understanding the unspoken cultural and procedural expectations of SELO inspectors, including hosting and on-site hospitality.

Our Solution: Full-Spectrum SELO Audit Support

Recognizing the high stakes of SELO license renewal, Inox Torres Group, S.L. engaged Cisema for comprehensive regulatory and strategic support.

  • Reviewed the Quality Management System
    Cisema led the review and upgrade of the customer’s quality management system in line with the latest Chinese requirements, including a comprehensive gap analysis and revision of key documentation.
  • Audit Simulation & Preparation
    A preparatory remote audit simulation was conducted, walking through every step of the audit to ensure full readiness ahead of the on-site inspection.
  • Delivered On-Site Bilingual & Regulatory Support
    During the on-site audit, Cisema provided continuous bilingual support, interpreting inspector questions in real time and translating regulatory nuances for the customer.
  • Provided Culturally Appropriate Inspector Hosting
    Cisema arranged culturally appropriate corporate hospitality, helping establish a respectful and positive tone for the inspection. The team remained onsite throughout all audit days, including the weekend, to ensure no detail was overlooked.

The Outcome: Successful Renewal Without Disruption

Through hands-on execution and close coordination, the SELO renewal process was completed smoothly and efficiently.

  • Secured CML Renewal with Full A2 Status
    Inox Torres Group, S.L. successfully renewed its China Manufacture License for pressure vessels, maintaining its Level A2 classification.
  • Executed the Project Efficiently
    Full regulatory preparation and audit execution were completed within six months.
  • Achieved Seamless Inspector Coordination
    SELO inspectors were hosted and coordinated smoothly, with culturally aligned engagement throughout the audit.
  • Secured Regulatory Continuity  
    The renewal avoided operational disruptions and ensured compliance with updated SELO requirements.

Expertise and Efficiency: Acting as an Extension of the Client Team

Cisema’s experienced consultants acted as an extension of Inox Torres Group, S.L.’s regulatory and quality teams, providing both regulatory expertise and strategic foresight. Inspector concerns were anticipated and addressed proactively, transforming a potentially stressful process into a streamlined, well-orchestrated engagement with Chinese authorities.

Hands-on mentoring throughout the project helped the customer gain confidence and clarity in managing future SELO audits.

Why Choose Cisema

  • Strategic Regulatory Expertise: Deep understanding of Chinese bureaucracy, evolving SELO requirements, and inspector expectations.
  • Mentorship & Training: Step-by-step guidance that supported the customer’s quality team throughout the process.
  • Corporate Hospitality Excellence: Culturally aligned hosting that supports successful audit outcomes in China.
  • Audit Readiness & Precision: Gap analysis, audit simulation, and documentation refinement to pass SELO reviews efficiently.
  • End-To-End Support: Full management of the audit process, from document revision to on-site interpretation.

Further Information

Explore Cisema’s China Special Equipment (SELO) Certification services.

Learn More
China Manufacture License Renewal for Level A2 Pressure Vessels
Previous
Previous

Latest Insights

View More

BPOM Clarifies Indonesia–US Trade Agreement Impact on Pharmaceutical Regulation

BPOM confirms pharmaceutical authorization, GMP oversight, and regulatory authority remain unchanged under the Indonesia–US trade agreement.

April 17, 2026
BPOM Clarifies Indonesia–US Trade Agreement Impact on Pharmaceutical Regulation
Laboratory scientist wearing a lab coat, protective goggles, gloves, and a blue hair cover carefully examining a small vial of liquid in a modern laboratory. A tray of sample vials sits on the bench in front.

Vietnam Cuts Advertising Red Tape for Healthcare Products

Vietnam’s MoH recently published Circular drops several healthcare advertising regulations and streamlines requirements for many categories.

April 17, 2026
Vietnam Cuts Advertising Red Tape for Healthcare Products

Malaysia Introduces Reliance and Priority Review Mechanisms for Additional Drug Indication Applications

Malaysia’s NPRA introduces reliance and priority review pathways for additional indications of registered innovator drugs.

April 17, 2026
Malaysia Introduces Reliance and Priority Review Mechanisms for Additional Drug Indication Applications

NMPA CDE Issues MRCT Benefit-Risk Assessment Guideline

China releases guiding principles for benefit-risk assessment using multi-regional clinical trial data to support global drug development.

April 17, 2026
NMPA CDE Issues MRCT Benefit-Risk Assessment Guideline

NMPA Issues Guidance on Subject Selection for Anti-Tumor Drug BE and PK Studies

China releases new subject selection guidance for anti-tumor drug bioequivalence and pharmacokinetic studies.

April 17, 2026
NMPA Issues Guidance on Subject Selection for Anti-Tumor Drug BE and PK Studies

Hong Kong Launches Pre-NDA Meetings Under the “1+” Drug Registration Mechanism

Hong Kong’s Department of Health introduces Pre-NDA meetings to streamline new drug registrations under the “1+” mechanism.

April 15, 2026
Hong Kong Launches Pre-NDA Meetings Under the “1+” Drug Registration Mechanism
Hong Kong Launches Pre-NDA Meetings Under the “1+” Drug Registration Mechanism
Previous
Previous

Get in Touch with Our Pharma Consultants

Speak with our pharma consultants to explore how our regulatory services, operational capabilities, and strategic expertise can help your organization navigate the region's complex pharmaceutical markets.

Request Proposal